EA202190661A1 - Агонисты фарнезоидного х-рецептора для лечения заболевания - Google Patents

Агонисты фарнезоидного х-рецептора для лечения заболевания

Info

Publication number
EA202190661A1
EA202190661A1 EA202190661A EA202190661A EA202190661A1 EA 202190661 A1 EA202190661 A1 EA 202190661A1 EA 202190661 A EA202190661 A EA 202190661A EA 202190661 A EA202190661 A EA 202190661A EA 202190661 A1 EA202190661 A1 EA 202190661A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharnesoid
receptor agonists
disease treatment
farnesoid
receptor
Prior art date
Application number
EA202190661A
Other languages
English (en)
Inventor
Кеннет Сонг
Хьюберт Чэн
Брэнди Вагнер
Николас Д. Смит
Original Assignee
Метакрайн, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метакрайн, Инк. filed Critical Метакрайн, Инк.
Publication of EA202190661A1 publication Critical patent/EA202190661A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к комбинированным терапиям с применением агонистов фарнезоидного Х-рецептора (FXR) и к способам применения их фармацевтических композиций для лечения состояний, заболеваний или нарушений, связанных с активностью фарнезоидного Х-рецептора.
EA202190661A 2018-09-18 2019-09-17 Агонисты фарнезоидного х-рецептора для лечения заболевания EA202190661A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862733008P 2018-09-18 2018-09-18
PCT/US2019/051604 WO2020061114A1 (en) 2018-09-18 2019-09-17 Farnesoid x receptor agonists for the treatment of disease

Publications (1)

Publication Number Publication Date
EA202190661A1 true EA202190661A1 (ru) 2021-08-13

Family

ID=69887939

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190661A EA202190661A1 (ru) 2018-09-18 2019-09-17 Агонисты фарнезоидного х-рецептора для лечения заболевания

Country Status (9)

Country Link
US (2) US20220047553A1 (ru)
EP (1) EP3852735A4 (ru)
JP (1) JP2022500396A (ru)
CN (1) CN113056266A (ru)
AU (1) AU2019344904A1 (ru)
CA (1) CA3112414A1 (ru)
EA (1) EA202190661A1 (ru)
MA (1) MA53661A (ru)
WO (1) WO2020061114A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016323992B2 (en) 2015-09-16 2021-05-06 Organovo, Inc. Farnesoid X receptor agonists and uses thereof
JP7258763B2 (ja) 2017-03-15 2023-04-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
SG11202102651SA (en) 2018-09-18 2021-04-29 Metacrine Inc Farnesoid x receptor agonists and uses thereof
CN114502198A (zh) * 2019-09-30 2022-05-13 诺华股份有限公司 包括使用fxr激动剂的治疗
CN114945361A (zh) 2020-01-15 2022-08-26 法国国家卫生及研究医学协会 Fxr激动剂在治疗丁型肝炎病毒感染中的用途
KR20210129517A (ko) * 2020-04-20 2021-10-28 경북대학교병원 Nadph 산화효소 1 저해제를 유효성분으로 포함하는 허혈-재관류 손상 예방 또는 치료용 조성물
KR20230024277A (ko) * 2020-05-13 2023-02-20 테른스 파마슈티칼스, 인크. 간 장애의 조합 치료
WO2021243526A1 (zh) * 2020-06-01 2021-12-09 苏州大学附属儿童医院 新生儿肠外营养相关性肝病特异性标志物lncRNA的应用
CN116615416A (zh) 2020-08-25 2023-08-18 伊莱利利公司 Ssao抑制剂的多晶型物
CN112402430A (zh) * 2020-12-11 2021-02-26 大连医科大学 泽泻醇b-23-醋酸酯在预防和治疗急性肾损伤中的应用
JP2023554524A (ja) * 2020-12-22 2023-12-27 ノースシー セラピューティクス ベスローテン フェンノートシャップ 非アルコール性脂肪性肝炎の治療のための酸素含有構造強化脂肪酸を含む組合せ療法
CA3204800A1 (en) 2021-01-14 2022-07-21 Raphael Darteil Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
JP2024508514A (ja) * 2021-03-02 2024-02-27 アリーナ ファーマシューティカルズ， インコーポレイテッド 選択的ｃｂ２受容体アゴニストによる処置の方法
TW202308629A (zh) 2021-04-28 2023-03-01 法商Ｅｎｙｏ製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效
TW202327589A (zh) * 2021-11-11 2023-07-16 美商拓臻製藥公司 肝病之組合療法
WO2024024156A1 (ja) * 2022-07-29 2024-02-01 国立大学法人北海道大学 脂質ナノ粒子および医薬組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
ES2614130T3 (es) * 2008-09-30 2017-05-29 Pfizer Inc. Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones
CA2803900A1 (en) * 2010-07-09 2012-01-12 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
US8697739B2 (en) * 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
JP2015501788A (ja) * 2011-11-08 2015-01-19 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇタンパク質共役Ｍａｓ受容体調節因子およびそれに関連する障害の処置
CN107921048A (zh) * 2015-05-27 2018-04-17 法玛克亚公司 自分泌运动因子抑制剂及其用途
WO2017049176A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
AU2016323992B2 (en) * 2015-09-16 2021-05-06 Organovo, Inc. Farnesoid X receptor agonists and uses thereof
JP2018532772A (ja) * 2015-09-16 2018-11-08 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびそれらの使用
WO2017049172A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3419624B1 (en) * 2016-02-22 2021-01-13 Novartis AG Methods for using fxr agonists
BR112019005985A2 (pt) * 2016-10-05 2019-06-25 Novartis Ag composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico
EP3596053B1 (en) * 2017-03-15 2023-08-16 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
US20200131129A1 (en) * 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof

Also Published As

Publication number Publication date
US20220047553A1 (en) 2022-02-17
AU2019344904A1 (en) 2021-04-15
CA3112414A1 (en) 2020-03-26
EP3852735A1 (en) 2021-07-28
US20220323414A1 (en) 2022-10-13
JP2022500396A (ja) 2022-01-04
EP3852735A4 (en) 2022-06-08
CN113056266A (zh) 2021-06-29
WO2020061114A1 (en) 2020-03-26
MA53661A (fr) 2021-07-28

Similar Documents

Publication Publication Date Title
EA202190661A1 (ru) Агонисты фарнезоидного х-рецептора для лечения заболевания
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
EA201792047A1 (ru) Новые соединения
EA201992083A1 (ru) Модуляторы соматостатина и их применения
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
EA201891799A1 (ru) Замещенные 1,2,3-триазолы в качестве nr2b-селективных модуляторов nmda
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
EA202091559A1 (ru) Способ получения модуляторов соматостатина
EA201891710A1 (ru) Терапевтические соединения
BR112019005985A2 (pt) composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico
BR112019004684A2 (pt) combinação de agonistas de fxr
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
BR112017024852A2 (pt) antagonistas de receptor nk-1/nk-3 duplo para o tratamento de doenças dependentes de hormônio sexual
EA202190094A1 (ru) Антитела против cd40 для применения в лечении аутоиммунного заболевания
EA202191115A1 (ru) Новые пиридазины
PH12021550671A1 (en) Prodrugs of cgrp antagonists
EA201992051A1 (ru) Агонисты фарнезоидного x-рецептора и их применение
EA202190660A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201991395A1 (ru) Новые композиции для лечения суставных нарушений